Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK510 + atezolizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NK510 + atezolizumab is a **combination therapy** under investigation for the treatment of advanced gastric cancer. NK510 is an investigational drug (modality not fully specified in public records) and atezolizumab is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor. The combination is being tested for its safety and efficacy, where NK510 is administered alongside atezolizumab, a PD-L1 inhibitor, with the goal of amplifying anti-tumor immune responses. Trials specifically mention use in relapsed and refractory advanced gastric cancers, with atezolizumab provided according to standard dosing instructions. The regimen design allows evaluation of NK510 both as monotherapy and combined with atezolizumab in separate trial arms[1].
- Other names
- NK510 + atezolizumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on NK510 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK510 + atezolizumab.